Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate

Y Isobe; K Sugimoto; A Masuda; Y Hamano; K Oshimi

doi:10.1111/j.1445-5994.2009.01947.x

Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate

Intern Med J. 2009 Jun;39(6):408-11. doi: 10.1111/j.1445-5994.2009.01947.x.

Authors

Y Isobe¹, K Sugimoto, A Masuda, Y Hamano, K Oshimi

Affiliation

¹ Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. [email protected]

PMID: 19580620
DOI: 10.1111/j.1445-5994.2009.01947.x

Abstract

Imatinib mesylate (IM) is currently used as the first therapeutic choice against chronic myelogenous leukaemia (CML). Because IM poorly penetrates the blood-brain barrier, IM-treated CML patients may have a potential risk of central nervous system (CNS) involvement. Here we report a case with lymphoid blast crisis isolated only in CNS after bacterial meningitis, although the patient achieved and maintained complete cytogenetic response by IM therapy. It is important to consider isolated CNS blast crisis as a possible event in IM-treated CML patients.

Publication types

Case Reports
Review

MeSH terms

Benzamides
Central Nervous System / drug effects
Central Nervous System / metabolism*
Central Nervous System Diseases / chemically induced
Central Nervous System Diseases / metabolism*
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
Male
Meningitis, Bacterial / chemically induced
Meningitis, Bacterial / metabolism
Middle Aged
Piperazines / adverse effects
Piperazines / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*

Substances

Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate